Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04473768
Other study ID # ID ITM202007
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2021
Est. completion date January 31, 2022

Study information

Verified date April 2022
Source Institute of Tropical Medicine, Belgium
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In sub-Saharan Africa, non-typhoidal Salmonella (NTS) are a frequent cause of bloodstream infection, display high levels of antibiotic resistance and have a high case fatality rate (15%). In Kisantu hospital in the Democratic Republic of Congo (DR Congo), NTS account for 75% of bloodstream infection in children and many children are co-infected with Plasmodium falciparum (Pf) malaria. NTS bloodstream infection presents as a non-specific severe febrile illness, which challenges early diagnosis and, as a consequence, prompt and appropriate antibiotic treatment.Moreover, at the first level of care, frontline health workers have limited expertise and diagnostic skills and, as a consequence, clinical danger signs that indicate serious bacterial infections are often overlooked. Basic handheld diagnostic instruments and point-of-care tests can help to reliably detect danger signs and improve triage, referral and the start of antibiotics, but there is need for field implementation and adoption to low-resource settings. Further, it is known that some clinical signs and symptoms are frequent in NTS bloodstream infections. The integration of these clinical signs and symptoms in a clinical decision support model can facilitate the diagnosis of NTS bloodstream infections and target antibiotic treatment. The investigators aim to develop such a clinical decision support model based on data from children under five years old admitted to Kisantu district referral hospital in the Democratic republic of the Congo. While developing the model, the investigators will focus on the signs and symptoms that can differentiate NTS bloodstream infection from severe Pf malaria and on the clinical danger signs that can be assessed by handheld diagnostic instruments and point-of-care tests. The deliverable will be a clinical decision support model ready to integrate in an electronic decision support system.


Recruitment information / eligibility

Status Completed
Enrollment 1880
Est. completion date January 31, 2022
Est. primary completion date January 31, 2022
Accepts healthy volunteers No
Gender All
Age group N/A to 5 Years
Eligibility Inclusion Criteria: 1. Be a child of > 28 days and < 5 years old 2. Be admitted to Kisantu Hospital 3. Having a blood cultured sampled according to the criteria for suspected bloodstream infection embedded in the blood culture surveillance, i.e. presence of objective fever, hypothermia or history of fever during past 48 hours + at least one of the following criteria: - Hypotension, confusion or increased respiratory rate - Suspicion of severe localized infection: pneumonia, meningitis, osteomyelitis, complicated urinary tract infection, abscess, skin/soft tissue infection or abdominal infection - Suspicion of typhoid fever - Suspicion of severe Pf malaria 4. Having a caregiver willing and able to provide written informed consent Exclusion Criteria: - None

Study Design


Locations

Country Name City State
Belgium Kisantu general referral hospital Antwerp

Sponsors (5)

Lead Sponsor Collaborator
Institute of Tropical Medicine, Belgium Hôpital St. Luc Kisantu, République Democratique du Congo, Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo, International Vaccine Institute, KU Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Predictive signs and symptoms Identify clinical signs and symptoms predictive for and differentiate between:
1.1. NTS bloodstream infection 1.2. severe Pf malaria mono-infection 1.3. NTS/Pf malaria co-infection 1.4. other-pathogen bloodstream infections 1.5. other causes of febrile illness requiring hospital admission
12 months
Primary Contribution of handheld diagnostics and point-of-care tests to NTS bloodstream infection diagnosis Assess the contribution of handheld diagnostic instruments and point-of-care tests to the detection of danger signs associated with NTS bloodstream infection 12 months
Primary Clinical decision support model for NTS bloodstream infection Develop a clinical decision support model for diagnosis of NTS bloodstream infection based on the predictive clinical signs and symptoms associated with NTS bloodstream infections 12 months
Secondary Contribution of handheld diagnostics and point-of-care tests to bloodstream infection diagnosis Assess the contribution of handheld diagnostic instruments and point-of-care tests to the detection of danger signs associated with all pathogen bloodstream infection (NTS and other-pathogen bloodstream infections combined) 12 months
Secondary Clinical decision support model for bloodstream infection Develop a clinical decision support model for diagnosis of bloodstream infection caused by all pathogens (NTS and other pathogens combined) 12 months
Secondary Case fatality Determine the clinical signs and symptoms associated with case fatality in NTS bloodstream infection and all pathogen bloodstream infections (NTS and other pathogen combined) 12 months
Secondary Geographical clustering Assess the geographical clustering of cases with NTS bloodstream infection 12 months
See also
  Status Clinical Trial Phase
Terminated NCT04130282 - VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine Phase 1
Completed NCT04049916 - Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission Phase 2/Phase 3
Active, not recruiting NCT03814616 - Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections Phase 2
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT05135273 - Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali Phase 1
Not yet recruiting NCT06083688 - Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi Phase 4
Recruiting NCT03511443 - Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections N/A
Completed NCT05550909 - Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali Phase 2
Recruiting NCT05306067 - Plasmodium Falciparum Genomic Intelligence in Mozambique
Completed NCT05081089 - Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali Phase 2
Recruiting NCT05150808 - Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania Phase 3
Recruiting NCT05757167 - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics Phase 4
Completed NCT01992900 - A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria Phase 2
Completed NCT04565184 - Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde Phase 4
Completed NCT03896724 - Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso Phase 1/Phase 2
Completed NCT03454048 - Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 N/A
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Completed NCT03138096 - Safety and Protective Efficacy of Pb(PfCS@UIS4) Phase 1/Phase 2
Recruiting NCT04271306 - Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. Phase 1
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.